GDC-0068 (RG7440, Ipatasertib)

GDC-0068 (RG7440 or Ipatasertib) is a novel, ATP-competitive Akt1/2/3 inhibitor with IC50 values of 5 nM, 18 nM and 8 nM, respectively. GDC-0068 selectively inhibits cell cycle progression and viability of cancer cell lines driven by PI3K/Akt signaling pathway, including those with defects of the tumor suppressor PTEN, oncogenic mutations in PIK3CA, and amplification of HER2. GDC-0068 blocks the phosphorylation of multiple downstream targets of Akt in human cancer cell lines.

Additional Information

Product Name: GDC-0068 (RG7440, Ipatasertib)
Also Known As: Ipatasertib, (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one
Catalog No.: F6170
Size: 5 mg
CAS: 1001264-89-6
Formula: C24H32ClN5O2
Molecular Weight: 458 g/mol
Form: Powder
Quality Assurance: >98% by HPLC and NMR
Source: Synthetic
Storage: Eligible for room temperature shipping. Store at -20°C upon receiving; protect from air and ligh
PDF Data Sheet: Download PDF datasheetMSDS
Image(s): N/A
Shipping Method: Room temperature shipping
References: Blake JF, et al. (2012) J Med Chem. 55(18):8110-27.

Details

GDC-0068 (RG7440 or Ipatasertib) is a novel, ATP-competitive Akt1/2/3 inhibitor with IC50 values of 5 nM, 18 nM and 8 nM, respectively. GDC-0068 selectively inhibits cell cycle progression and viability of cancer cell lines driven by PI3K/Akt signaling pathway, including those with defects of the tumor suppressor PTEN, oncogenic mutations in PIK3CA, and amplification of HER2. GDC-0068 blocks the phosphorylation of multiple downstream targets of Akt in human cancer cell lines.

Solubility:
> 20 mg/ml in DMSO